Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 17/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.55 |
| ▸ | PDE4A | P27815 | 1/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.55 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5831429 | 0.90 | ADORA2B (0.52) | ADORA2BADORA2AADORA3PDE4APDE4B | |
| SCHEMBL27206789 | 0.89 | ADORA2B (0.59) | ADORA2BADORA2AADORA3PDE4APDE4B | |
| SCHEMBL8356656 | 0.88 | ADORA2B (0.52) | ADORA2BADORA2AADORA3PDE4APDE4B | |
| SCHEMBL3848063 | 0.85 | ADORA2B (0.60) | ADORA2BADORA2AADORA3PDE4APDE4B | |
| SCHEMBL27302135 | 0.81 | ADORA2B (0.60) | ADORA2BADORA2AADORA3PDE4APDE4B | |
| SCHEMBL27713795 | 0.77 | SIRT1 (0.68) | ADORA2BADORA2AADORA1POLB | |
| SCHEMBL9904030 | 0.77 | ADORA2B (0.55) | ADORA2BADORA2AADORA3PDE4APDE4B | |
| SCHEMBL538419 | 0.76 | ADORA2B (0.57) | ADORA2BADORA2AADORA3PDE4APDE4B | |
| SCHEMBL1892013 | 0.76 | POLB (0.49) | ADORA2BADORA2AADORA3PDE4APDE4B | |
| SCHEMBL2958488 | 0.76 | ADORA2A (0.58) | ADORA2BADORA2AADORA3PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106797-A1 | Novel xanthines having adenosine A1-receptor antagonist properties | ARYX THERAPEUTICS | 2004-06-03 | — | — | US | claimed |
| WO-2004009594-A2 | XANTHINE DERIVATIVES HAVING ADENOSINE A1-RECEPTOR ANTAGONIST PROPERTIES | ARYX THERAPEUTICS (US) | 2004-01-29 | — | — | WO | claimed |
| WO-1999031101-A1 | ADENOSINE RECEPTOR ANTAGONISTS WITH IMPROVED BIOACTIVITY | UNIVERSITY OF SOUTH FLORIDA (US) | 1999-06-24 | — | — | WO | claimed |
| US-20230035892-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | FLAGSHIP PIONEERING, INC. | 2023-02-02 | — | — | US | disclosed |
| US-11274158-B2 | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20220033490-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER USING CHRNA6 INHIBITORS | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2022-02-03 | — | — | US | disclosed |
| US-11208475-B1 | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using serotonin receptor activators | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20210283217-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-09-16 | — | — | US | disclosed |
| US-11059886-B1 | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using GRM8 activators | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210177823-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-06-17 | — | — | US | disclosed |
| US-11034751-B1 | Methods and compositions for treating cancer using serotonin receptor inhibitors | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20070207979-A1 | Method of using adenosine receptor blockers during tissue ablation | SHERWOOD SERVICES AG | 2007-09-06 | — | — | US | disclosed |
| CN-1684686-A | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof | UNIV CALIFORNIA (US) | 2005-10-19 | — | — | CN | disclosed |
| US-6545002-B1 | Treating asthma, diarrhea, insulin resistance, diabetes, ischemia/reprefusion injuries, diabetic retinopathy or hyperbaric oxygen-induced retinopathy | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2003-04-08 | — | — | US | disclosed |
| EP-1051192-A2 | METHODS FOR THE PREVENTION AND TREATMENT OF FIBROSIS AND SCLEROSIS | Link Technology, Inc. (US) | 2000-11-15 | — | — | EP | disclosed |
| WO-1999038532-A2 | METHODS FOR THE PREVENTION AND TREATMENT OF FIBROSIS AND SCLEROSIS | LINK TECHNOLOGY, INC. (US) | 1999-08-05 | — | — | WO | disclosed |
| WO-1999031101-A1 | ADENOSINE RECEPTOR ANTAGONISTS WITH IMPROVED BIOACTIVITY | UNIVERSITY OF SOUTH FLORIDA (US) | 1999-06-24 | — | — | WO | disclosed |
| EP-0619316-B1 | Xanthine derivatives | KYOWA HAKKO KOGYO KK (JP) | 1998-08-12 | — | — | EP | disclosed |
| EP-0619316-A1 | Xanthine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1994-10-12 | — | — | EP | disclosed |
| WO-1993021949-A1 | IMMUNOLOGICAL DETECTION AND QUANTIFICATION OF 8-(CYCLOALKYL OR AROMATIC) SUBSTITUTED-1,3-DIPROPYLXANTHINES | VANDERBILT UNIVERSITY (US) | 1993-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033490-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER USING CHRNA6 INHIBITORS | CHRNA6, CHRNA1, CHRNB1 | ADORA2B 76/4885ADORA2A 90/4885ADORA3 31/4885 |
| US-20070207979-A1 | Method of using adenosine receptor blockers during tissue ablation | ADORA2A, ADORA2B, ADORA3 | ADORA2B 2/4885ADORA2A 1/4885ADORA3 3/4885 |
| US-20040106797-A1 | Novel xanthines having adenosine A1-receptor antagonist properties | ADORA1, ADORA2A, ADORA3 | ADORA2B 4/4885ADORA2A 2/4885ADORA3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.